Loading
A 2018 review that gathered the cell-culture and animal experiments on ivermectin and argued it was ready for cancer trials; those trials began five years later and have not reported.
The review summarises in vitro and in vivo experiments in which ivermectin acted on multidrug resistance protein, Akt/mTOR and WNT-TCF signalling, purinergic receptors, PAK1, the SIN3A and SIN3B epigenetic regulators, RNA helicase and chloride channels, and on cancer stem-like cells (Juarez review 2018). It argues that the concentrations used are reachable in people on the basis of pharmacokinetic studies in healthy and parasite-infected volunteers, and that this could allow a rapid move into trials (Juarez review 2018).
This is the paper the online claims usually trace back to. It is a call for trials, not evidence that the drug works in people, and the trials it called for are still running.
Shares In vitro and in vivo, Systematic drug repurposing, Preclinical, Ivermectin.
Shares Fenbendazole, ivermectin and other internet 'repurposed cures', Systematic drug repurposing, Ivermectin.
Shares In vitro and in vivo, Preclinical, Ivermectin.
Shares Fenbendazole, ivermectin and other internet 'repurposed cures', Preclinical, Ivermectin.
Shares Fenbendazole, ivermectin and other internet 'repurposed cures', Ivermectin.
Shares Fenbendazole, ivermectin and other internet 'repurposed cures', Ivermectin.
Shares Fenbendazole, ivermectin and other internet 'repurposed cures', Ivermectin.
Shares In vitro and in vivo, Preclinical.